Comparison of two methods of administration of deferoxamine (intravenous and subcutaneous) in terms of impact on reducing iron overload in thalassemia patients who have suffered heart failure.

Comparative study of intravenous and subcutaneous high-dose desferal on Iron overload in thalassemia major patient with decrease in Ejection-Fraction.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201206289827N2

Enrollment

Registered

2012-07-14

Start date

2011-11-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron overload.. Abnormal level of blood mineral.

Interventions

Intervention 1: Case Group: Desferal (Desferrioxamine Mesylate 500mg) intravenous administration will be performed for a week, 200 mg/kg/day. Intervention 2: Control group:Desferal (Desferrioxamine Me

Treatment - Drugs

Case Group: Desferal (Desferrioxamine Mesylate 500mg) intravenous administration will be performed for a week, 200 mg/kg/day.

Control group:Desferal (Desferrioxamine Mesylate 500mg) subcutaneous administration will be performed for a week, 200 mg/kg/day.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: suffering major Thalassemia and cardiac ejection fraction less than 50%. Exclusion criteria: inflammatory disease; anemia and liver disorders.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum ferritin. Timepoint: 1 week after intervention (desferal administration). Method of measurement: Use of ELISA method, unit will be mg/L.	—

Secondary

Measure	Time frame
Cardiac Ejection Fraction. Timepoint: 2 weeks after intervention. Method of measurement: Using Ecocardiography, the unit will be "percent".	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKhosro Karimi

Kermanshah University of Medical Sciences and Health Services

mehramini143@kums.ac.ir+98 83 1427 6302

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026